ИНТЕЛОН-02, NCT06232434: An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II |
|
|
| Not yet recruiting | 2/3 | 120 | RoW | Prospidelong, chemotherapy | Research Institute for Physical Chemical Problems of the Belarusian State University, The state institution N. N. Alexandrov National Cancer Centre of Belarus, Unitary Enterprise UNITEHPROM BSU | Gastric Cancer With Peritoneal Dissemination | 12/24 | 12/24 | | |
